Lv5
830 积分 2020-09-29 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
1个月前
已完结
ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
1个月前
已完结
618 Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications
2个月前
已完结
Restoring rapid natural bimanual typing with a neuroprosthesis after paralysis
2个月前
已完结
Magnetic NeuroRing: a portable adaptive brain-computer interface for real-time transcranial magnetic stimulation in post-stroke motor rehabilitation
2个月前
已完结
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
2个月前
已完结
Lines of Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: The New Paradigm
2个月前
已完结
Survival outcomes with enfortumab vedotin–containing regimens in metastatic urothelial carcinoma: A systematic review and meta-analysis
2个月前
已完结
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial
2个月前
已完结
Progress in the combined application of Brain-Computer Interface and non-invasive brain stimulation for post-stroke motor recovery
4个月前
已完结
皖公网安备34019202002308
